Flavia Michelini
Research Subjects
Flavia Michelini has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
- Vicky Makker
Department of Medicine, Weill Cornell Medical College, New York, New York
15 shared publications - Ana Oaknin
Vall d’Hebron Institute of Oncology (VHIO) 7 Medical Oncology Service, Vall d’Hebron Barcelona Hospital Campus, Instituto de Investigación Sanitaria Hospital Universitari Vall d’Hebron (IIS IR-HUVH) Barcelona, Spain
10 shared publications - Funda Meric-Bernstam
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA
10 shared publications - Jung-Yun Lee
Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea
10 shared publications - Do-Youn Oh
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
9 shared publications - Lindsey Jung
Oncology Biometrics, Oncology R&D, AstraZeneca, Gaithersburg, Maryland
9 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Concordancea rates between local and central HER2 test results and tumor type/cohort.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Concordancea rates between local and central HER2 test results and tumor type/cohort.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Concordance between local and central HER2 IHC test results. The protocol did not specify the use of specific antibodies for local testing. Central HER2 IHC testing utilized the HercepTest (Dako, Agilent), with samples scored according to gastric cancer–specific criteria. Unknown IHC status by central test result includes patients whose samples were unevaluable (for various technical reasons) and may include patients for whom a sample was not provided for central testing. Overall concordance between local and central HER2 results: IHC 3+, 58.6%; IHC 2+, 54.5%; and IHC 3+ and IHC 2+ combined, 73.4%.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Concordance between local and central HER2 IHC test results. The protocol did not specify the use of specific antibodies for local testing. Central HER2 IHC testing utilized the HercepTest (Dako, Agilent), with samples scored according to gastric cancer–specific criteria. Unknown IHC status by central test result includes patients whose samples were unevaluable (for various technical reasons) and may include patients for whom a sample was not provided for central testing. Overall concordance between local and central HER2 results: IHC 3+, 58.6%; IHC 2+, 54.5%; and IHC 3+ and IHC 2+ combined, 73.4%.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table 5 from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Efficacy by local and central HER2 IHC test results.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 5 from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Efficacy by local and central HER2 IHC test results.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Concordancea rates between central HER2 HercepTest results and local HER2 HercepTest or Roche HER2 4B5 assay test results.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Concordancea rates between central HER2 HercepTest results and local HER2 HercepTest or Roche HER2 4B5 assay test results.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Purpose:Accurate HER2 status assessment is crucial to identify patients with HER2-expressing tumors. In this post hoc analysis of DESTINY-PanTumor02 (NCT04482309), we report concordance between local and central HER2 immunohistochemistry (IHC) results.Patients and Methods:This open-label, phase II study evaluated trastuzumab deruxtecan (T-DXd; 5.4 mg/kg once every 3 weeks) for HER2-expressing (IHC 3+/2+ by local or central testing) locally advanced, unresectable, or metastatic solid tumors after ≥1 systemic treatment or without alternative treatments.Results:In total, 267 patients received T-DXd; 75.7% were enrolled based on local test results. Concordance between local and central HER2 test results was 58.6% for IHC 3+, 54.5% for IHC 2+, and 73.4% for IHC 3+ and IHC 2+ tumors combined.Conclusions:The moderate concordance observed between local and central IHC testing in DESTINY-PanTumor02 highlights the need for a validated diagnostic test and standardized algorithm for HER2 status assessment in solid tumors to ensure appropriate patient identification for HER2-directed therapies.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Purpose:Accurate HER2 status assessment is crucial to identify patients with HER2-expressing tumors. In this post hoc analysis of DESTINY-PanTumor02 (NCT04482309), we report concordance between local and central HER2 immunohistochemistry (IHC) results.Patients and Methods:This open-label, phase II study evaluated trastuzumab deruxtecan (T-DXd; 5.4 mg/kg once every 3 weeks) for HER2-expressing (IHC 3+/2+ by local or central testing) locally advanced, unresectable, or metastatic solid tumors after ≥1 systemic treatment or without alternative treatments.Results:In total, 267 patients received T-DXd; 75.7% were enrolled based on local test results. Concordance between local and central HER2 test results was 58.6% for IHC 3+, 54.5% for IHC 2+, and 73.4% for IHC 3+ and IHC 2+ tumors combined.Conclusions:The moderate concordance observed between local and central IHC testing in DESTINY-PanTumor02 highlights the need for a validated diagnostic test and standardized algorithm for HER2 status assessment in solid tumors to ensure appropriate patient identification for HER2-directed therapies.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table 4 from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Concordancea rates between central HER2 IHC test results and local test results according to biopsy or resection.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 4 from Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Concordancea rates between central HER2 IHC test results and local test results according to biopsy or resection.
- Open Access
- 9 April 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (13) , 2628-2636
Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Purpose: Accurate HER2 status assessment is crucial to identify patients with HER2-expressing tumors. In this post hoc analysis of DESTINY-PanTumor02 (NCT04482309), we report concordance between local and central HER2 immunohistochemistry (IHC) results. Patients and Methods: This open-label, phase II study evaluated trastuzumab deruxtecan (T-DXd; 5.4 mg/kg once every 3 weeks) for HER2-expressing (IHC 3+/2+ by local or central testing) locally advanced, unresectable, or metastatic solid tumors after ≥1 systemic treatment or without alternative treatments. Results: In total, 267 patients received T-DXd; 75.7% were enrolled based on local test results. Concordance between local and central HER2 test results was 58.6% for IHC 3+, 54.5% for IHC 2+, and 73.4% for IHC 3+ and IHC 2+ tumors combined. Conclusions: The moderate concordance observed between local and central IHC testing in DESTINY-PanTumor02 highlights the need for a validated diagnostic test and standardized algorithm for HER2 status assessment in solid tumors to ensure appropriate patient identification for HER2-directed therapies.
- 9 April 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (13) , 2628-2636
Open AccessPost Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Purpose: Accurate HER2 status assessment is crucial to identify patients with HER2-expressing tumors. In this post hoc analysis of DESTINY-PanTumor02 (NCT04482309), we report concordance between local and central HER2 immunohistochemistry (IHC) results. Patients and Methods: This open-label, phase II study evaluated trastuzumab deruxtecan (T-DXd; 5.4 mg/kg once every 3 weeks) for HER2-expressing (IHC 3+/2+ by local or central testing) locally advanced, unresectable, or metastatic solid tumors after ≥1 systemic treatment or without alternative treatments. Results: In total, 267 patients received T-DXd; 75.7% were enrolled based on local test results. Concordance between local and central HER2 test results was 58.6% for IHC 3+, 54.5% for IHC 2+, and 73.4% for IHC 3+ and IHC 2+ tumors combined. Conclusions: The moderate concordance observed between local and central IHC testing in DESTINY-PanTumor02 highlights the need for a validated diagnostic test and standardized algorithm for HER2 status assessment in solid tumors to ensure appropriate patient identification for HER2-directed therapies.
- Open Access
- 11 February 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-12
HER2 testing in multiple solid tumor types: concordance of immunohistochemistry scores between three HER2 scoring algorithms
Accurate human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scoring is crucial to identify patients for HER2-directed therapy; however, validated HER2 scoring guidelines are lacking for non-breast/gastric solid tumors. We investigated concordance in IHC scores from independent pathologists using three different scoring algorithms in non-gastric/breast solid tumors. Whole-slide scans of HER2-stained tumor samples from DESTINY-PanTumor02 (NCT04482309) and a commercial pan-tumor sample set were scored by three independent, board-certified pathologists using American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) scoring algorithms for gastric (reference) and breast cancers, and a clinical trial-based algorithm for endometrial cancers (evaluated for endometrial tumors only). The pathologists evaluated 488 samples from multiple solid tumor types. Mean positive percentage agreement (PPA; across pathologists) between the breast and gastric algorithms was higher for samples scored as IHC 3 + or IHC 0 compared with IHC 2 + or IHC 1 + . Inter-pathologist PPA for each algorithm was greatest in samples scored as IHC 3 + and IHC 0. The majority of inter-pathologist pairwise comparisons had Cohen’s κ coefficient values > 0.4 when using the gastric or breast algorithm to determine IHC scores, indicating at least moderate agreement between pathologists; Cohen’s κ coefficient values were generally lower (range 0.17–0.43) for the endometrial algorithm. ASCO/CAP scoring algorithms for gastric and breast cancer were comparable for identifying HER2 IHC 3 + tumors; lower concordance was observed for IHC 2 + /1 + tumors. These findings highlight a real-world issue of inter-pathologist variability and emphasize a need for greater awareness of best scoring practices.
- 11 February 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-12
Open AccessHER2 testing in multiple solid tumor types: concordance of immunohistochemistry scores between three HER2 scoring algorithms
Accurate human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scoring is crucial to identify patients for HER2-directed therapy; however, validated HER2 scoring guidelines are lacking for non-breast/gastric solid tumors. We investigated concordance in IHC scores from independent pathologists using three different scoring algorithms in non-gastric/breast solid tumors. Whole-slide scans of HER2-stained tumor samples from DESTINY-PanTumor02 (NCT04482309) and a commercial pan-tumor sample set were scored by three independent, board-certified pathologists using American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) scoring algorithms for gastric (reference) and breast cancers, and a clinical trial-based algorithm for endometrial cancers (evaluated for endometrial tumors only). The pathologists evaluated 488 samples from multiple solid tumor types. Mean positive percentage agreement (PPA; across pathologists) between the breast and gastric algorithms was higher for samples scored as IHC 3 + or IHC 0 compared with IHC 2 + or IHC 1 + . Inter-pathologist PPA for each algorithm was greatest in samples scored as IHC 3 + and IHC 0. The majority of inter-pathologist pairwise comparisons had Cohen’s κ coefficient values > 0.4 when using the gastric or breast algorithm to determine IHC scores, indicating at least moderate agreement between pathologists; Cohen’s κ coefficient values were generally lower (range 0.17–0.43) for the endometrial algorithm. ASCO/CAP scoring algorithms for gastric and breast cancer were comparable for identifying HER2 IHC 3 + tumors; lower concordance was observed for IHC 2 + /1 + tumors. These findings highlight a real-world issue of inter-pathologist variability and emphasize a need for greater awareness of best scoring practices.